Trial site
Zhongshan City People's Hospital
Zhongshan, Guangdong 528445, ChinaNot linked to an institution yet
- 15running trials
- 1closed trial
The trials here
What the 16 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 22 trials
- Phase 1/21 trial
- Phase 41 trial
- Status
- Recruiting6 trials
- Active, not recruiting5 trials
- Not yet recruiting4 trials
- Completed1 trial
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2 trials
- Guangdong Association of Clinical Trials2 trials
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.2 trials
- Sun Yat-sen University2 trials
- Daiichi Sankyo1 trial
- and 7 more
Running trials
Not yet recruiting
Efficacy Analysis of Transcutaneous Auricular Vagus Nerve Stimulation Combined With Tailor-Made Notched Music Therapy in the Treatment of Chronic Subjective Tinnitus
NCT07794462· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Guoping Chen
Recruiting
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
NCT07367529· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Guinan Lin, Master
Recruiting
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT07347600· Hoffmann-La Roche· Source
Recruiting
TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
NCT06829784· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Contact: Jianping Liang, Bachelor
Active, not recruiting
A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06707883· Phase 2· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Active, not recruiting
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
NCT06680921· Phase 3· Jiangsu Simcere Pharmaceutical Co., Ltd.· Source
Recruiting
Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
NCT06445088· Sun Yat-sen University· Source
Contact: Min-Yi Fu
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776· Daiichi Sankyo· Source
Contact: Principal Investigator
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· Phase 3· LeonaBio· Source
Contact: Shihui Ma
Recruiting
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
NCT06551220· Sun Yat-sen University· Source
Contact: Shien Cui
Recruiting
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
NCT05536505· Phase 2· Guangdong Association of Clinical Trials· Source
Contact: Yi Liang, MD
Recruiting
Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD
NCT05457049· Guangdong Association of Clinical Trials· Source
Contact: Yi Liang, MD
Active, not recruiting
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
NCT05365178· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Active, not recruiting
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493· Phase 3· Loxo Oncology, Inc.· Source
Active, not recruiting
ASPIrin in Reducing Events in Dialysis ( ASPIRED )
NCT04381143· Phase 4· Guangdong Provincial People's Hospital· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error